On Monday, Repligen Corp (NASDAQ: RGEN) opened lower -12.02% from the last session, before settling in for the closing price of $155.70. Price fluctuations for RGEN have ranged from $113.50 to $203.13 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 29.32% over the past five years. Company’s average yearly earnings per share was noted 8.13% at the time writing. With a float of $52.91 million, this company’s outstanding shares have now reached $56.03 million.
Let’s look at the performance matrix of the company that is accounted for 1783 employees. In terms of profitability, gross margin is 48.69%, operating margin of -6.5%, and the pretax margin is -5.17%.
Repligen Corp (RGEN) Insider Updates
A key investor’s attitude towards the stock of the Medical Instruments & Supplies industry is another important factor to consider. The insider ownership of Repligen Corp is 5.57%, while institutional ownership is 101.01%. The most recent insider transaction that took place on Nov 21 ’24, was worth 3,386,439. In this transaction Director of this company sold 24,246 shares at a rate of $139.67, taking the stock ownership to the 139,840 shares. Before that another transaction happened on Nov 21 ’24, when Company’s Executive Chairman proposed sale 24,246 for $139.66, making the entire transaction worth $3,386,311.
Repligen Corp (RGEN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 8.13% per share during the next fiscal year.
Repligen Corp (NASDAQ: RGEN) Trading Performance Indicators
Check out the current performance indicators for Repligen Corp (RGEN). In the past quarter, the stock posted a quick ratio of 8.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.10. Likewise, its price to free cash flow for the trailing twelve months is 58.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.46, a number that is poised to hit 0.35 in the next quarter and is forecasted to reach 2.24 in one year’s time.
Technical Analysis of Repligen Corp (RGEN)
Repligen Corp (NASDAQ: RGEN) saw its 5-day average volume 0.88 million, a positive change from its year-to-date volume of 0.64 million. As of the previous 9 days, the stock’s Stochastic %D was 36.98%. Additionally, its Average True Range was 8.65.
During the past 100 days, Repligen Corp’s (RGEN) raw stochastic average was set at 25.36%, which indicates a significant increase from 3.92% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.74% in the past 14 days, which was higher than the 51.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $156.61, while its 200-day Moving Average is $146.26. Nevertheless, the first resistance level for the watch stands at $147.74 in the near term. At $158.49, the stock is likely to face the second major resistance level. The third major resistance level sits at $164.51. If the price goes on to break the first support level at $130.96, it is likely to go to the next support level at $124.94. Assuming the price breaks the second support level, the third support level stands at $114.19.
Repligen Corp (NASDAQ: RGEN) Key Stats
There are currently 56,027K shares outstanding in the company with a market cap of 7.68 billion. Presently, the company’s annual sales total 634,440 K according to its annual income of -25,510 K. Last quarter, the company’s sales amounted to 167,550 K and its income totaled -33,870 K.
